142 related articles for article (PubMed ID: 22385606)
21. [Clinical characteristics in adult acute myeloid leukemia with isocitrate dehydrogenase gene mutation].
Wang RX; Wu DP; Chen SN; He J; Xu Y; Wang XL; Yin J; Tian H; Tian XP; Sun AN
Zhonghua Yi Xue Za Zhi; 2013 Mar; 93(10):751-5. PubMed ID: 23755812
[TBL] [Abstract][Full Text] [Related]
22. Isocitrate dehydrogenase mutations in myeloid malignancies.
Medeiros BC; Fathi AT; DiNardo CD; Pollyea DA; Chan SM; Swords R
Leukemia; 2017 Feb; 31(2):272-281. PubMed ID: 27721426
[TBL] [Abstract][Full Text] [Related]
23. Emerging drug profile: Krebs cycle and cancer: IDH mutations and therapeutic implications.
Lee S; Urman A; Desai P
Leuk Lymphoma; 2019 Nov; 60(11):2635-2645. PubMed ID: 30958073
[TBL] [Abstract][Full Text] [Related]
24. Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1.
Liu X; Kato Y; Kaneko MK; Sugawara M; Ogasawara S; Tsujimoto Y; Naganuma Y; Yamakawa M; Tsuchiya T; Takagi M
Cancer Med; 2013 Dec; 2(6):803-14. PubMed ID: 24403254
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical Detection and Molecular Characterization of IDH-mutant Sinonasal Undifferentiated Carcinomas.
Mito JK; Bishop JA; Sadow PM; Stelow EB; Faquin WC; Mills SE; Krane JF; French CA; Fletcher CDM; Hornick JL; Sholl LM; Jo VY
Am J Surg Pathol; 2018 Aug; 42(8):1067-1075. PubMed ID: 29683816
[TBL] [Abstract][Full Text] [Related]
26. Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations.
Lin TL; Nagata Y; Kao HW; Sanada M; Okuno Y; Huang CF; Liang DC; Kuo MC; Lai CL; Lee EH; Shih YS; Tanaka H; Shiraishi Y; Chiba K; Lin TH; Wu JH; Miyano S; Ogawa S; Shih LY
Haematologica; 2014 Jan; 99(1):28-36. PubMed ID: 23996483
[TBL] [Abstract][Full Text] [Related]
27. Prevalence and Clinical Effect of IDH1 and IDH2 Mutations Among Cytogenetically Normal Acute Myeloid Leukemia Patients.
Aref S; Kamel Areida el S; Abdel Aaal MF; Adam OM; El-Ghonemy MS; El-Baiomy MA; Zeid TA
Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):550-5. PubMed ID: 26189213
[TBL] [Abstract][Full Text] [Related]
28. Development of Novel Therapeutics Targeting Isocitrate Dehydrogenase Mutations in Cancer.
Sharma H
Curr Top Med Chem; 2018; 18(6):505-524. PubMed ID: 29773061
[TBL] [Abstract][Full Text] [Related]
29. IDH mutations in cancer and progress toward development of targeted therapeutics.
Dang L; Yen K; Attar EC
Ann Oncol; 2016 Apr; 27(4):599-608. PubMed ID: 27005468
[TBL] [Abstract][Full Text] [Related]
30. [Clinical significance of IDH1 and IDH2 mutations in patients with acute myeloid leukemia].
Mi RH; Lu XD; Wei XD; Fan RH; Yin QS; Hu JY; Wang Q; Song YP
Zhonghua Xue Ye Xue Za Zhi; 2011 Sep; 32(9):610-3. PubMed ID: 22338155
[TBL] [Abstract][Full Text] [Related]
31. Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm.
Issa GC; DiNardo CD
Blood Cancer J; 2021 Jun; 11(6):107. PubMed ID: 34083508
[TBL] [Abstract][Full Text] [Related]
32. IDH1 and IDH2 mutations in patients with acute myeloid leukemia: Suitable targets for minimal residual disease monitoring?
Petrova L; Vrbacky F; Lanska M; Zavrelova A; Zak P; Hrochova K
Clin Biochem; 2018 Nov; 61():34-39. PubMed ID: 30176240
[TBL] [Abstract][Full Text] [Related]
33. Oncogenetic landscape and clinical impact of IDH1 and IDH2 mutations in T-ALL.
Simonin M; Schmidt A; Bontoux C; Dourthe MÉ; Lengliné E; Andrieu GP; Lhermitte L; Graux C; Grardel N; Cayuela JM; Huguet F; Arnoux I; Ducassou S; Macintyre E; Gandemer V; Dombret H; Petit A; Ifrah N; Baruchel A; Boissel N; Asnafi V
J Hematol Oncol; 2021 May; 14(1):74. PubMed ID: 33941203
[TBL] [Abstract][Full Text] [Related]
34. Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia.
Thol F; Damm F; Wagner K; Göhring G; Schlegelberger B; Hoelzer D; Lübbert M; Heit W; Kanz L; Schlimok G; Raghavachar A; Fiedler W; Kirchner H; Heil G; Heuser M; Krauter J; Ganser A
Blood; 2010 Jul; 116(4):614-6. PubMed ID: 20421455
[TBL] [Abstract][Full Text] [Related]
35. Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of CDX2 and IDH1/2 mutations.
Yasuda T; Sanada M; Kawazu M; Kojima S; Tsuzuki S; Ueno H; Iwamoto E; Iijima-Yamashita Y; Yamada T; Kanamori T; Nishimura R; Kuwatsuka Y; Takada S; Tanaka M; Ota S; Dobashi N; Yamazaki E; Hirose A; Murayama T; Sumi M; Sato S; Tange N; Nakamura Y; Katsuoka Y; Sakaida E; Kawamata T; Iida H; Shiraishi Y; Nannya Y; Ogawa S; Taniwaki M; Asou N; Hatta Y; Kiyoi H; Matsumura I; Horibe K; Mano H; Naoe T; Miyazaki Y; Hayakawa F
Blood; 2022 Mar; 139(12):1850-1862. PubMed ID: 34695176
[TBL] [Abstract][Full Text] [Related]
36. [Prognostic significance of different IDH mutations and accompanying gene mutations in patients with acute myeloid leukemia].
Wu RY; Xie XS; Wei Y; Jang ZX; Chen DD; Sun H; Wan DM; Liu YF; Sun L
Zhonghua Xue Ye Xue Za Zhi; 2021 Jan; 42(1):39-44. PubMed ID: 33677867
[No Abstract] [Full Text] [Related]
37. Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Platt MY; Fathi AT; Borger DR; Brunner AM; Hasserjian RP; Balaj L; Lum A; Yip S; Dias-Santagata D; Zheng Z; Le LP; Graubert TA; Iafrate AJ; Nardi V
J Mol Diagn; 2015 Nov; 17(6):661-8. PubMed ID: 26331834
[TBL] [Abstract][Full Text] [Related]
38. Outcomes for Patients With IDH-Mutated Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.
Chen EC; Li S; Eisfeld AK; Luskin MR; Mims A; Jones D; Antin JH; Cutler CS; Koreth J; Ho VT; Gooptu M; Romee R; El-Jawahri A; McAfee SL; DeFilipp Z; Soiffer RJ; Chen YB; Fathi AT
Transplant Cell Ther; 2021 Jun; 27(6):479.e1-479.e7. PubMed ID: 33840625
[TBL] [Abstract][Full Text] [Related]
39. Clinical prognostic value of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in glioblastoma.
Mistry AM; Vnencak-Jones CL; Mobley BC
J Neurooncol; 2018 Jun; 138(2):307-313. PubMed ID: 29423539
[TBL] [Abstract][Full Text] [Related]
40. IDH2 mutation in gliomas including novel mutation.
Koh J; Cho H; Kim H; Kim SI; Yun S; Park CK; Lee SH; Choi SH; Park SH
Neuropathology; 2015 Jun; 35(3):236-44. PubMed ID: 25495392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
